Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
Italy
Italy- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
22 trials match your criteria
Recruiting
Primary progressive multiple sclerosis
RecruitingInvestigational
Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis
Investigational
- Disease:Primary progressive multiple sclerosis
- Substances:–
Countries:Italy
Italy- Participants:18–64 years
Recruiting
Dementia Alzheimer's type
RecruitingInvestigational
Study of VHB937 to evaluate its effects on cognition and function in people with early Alzheimer's Disease over 72 weeks
Investigational
- Disease:Dementia Alzheimer's type
- Substances:VHB937
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:VHB937
Recruiting
Multiple sclerosis
RecruitingInvestigationalNo placebo
Safety and Feasibility of Home Use On-Body Injection System for Subcutaneous Ocrelizumab in Adults with Multiple Sclerosis
InvestigationalNo placebo
- Disease:Multiple sclerosis
- Substances:Ocrelizumab
Countries:Italy
Italy- Participants:18–64 years
- Substances:Ocrelizumab
Recruiting
Psychotic disorder+2
RecruitingInvestigational
Study on ITI-1284 for Treating Psychosis in Alzheimer's Patients
Investigational
- Disease:Psychotic disorderDementia of the Alzheimer's type with delusions+1
- Substances:Iti-1284
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Iti-1284
Recruiting
Radiologically isolated syndrome
RecruitingRegistered drug
Study of BCG Vaccine and Sodium Chloride for Patients with Radiologically Isolated Syndrome (RIS)
Registered drug
- Disease:Radiologically isolated syndrome
- Substances:Sodium ChlorideLive Bcg Bacilli (Bacillus Calmette-Guerin), Brasilian Moreau Substrain
Countries:Italy
Italy- Participants:18–64 years
- Substances:Sodium Chloride
Recruiting
Dementia Alzheimer's type
RecruitingInvestigationalNo placebo
Long-Term Safety Study of ACP-204 for Adults with Alzheimer's Disease Psychosis
InvestigationalNo placebo
- Disease:Dementia Alzheimer's type
- Substances:Acp-204 Tartrate
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Acp-204 Tartrate
Not yet recruiting
Relapsing-remitting multiple sclerosis
Not yet recruitingRegistered drugNo placebo
Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis
Registered drugNo placebo
- Disease:Relapsing-remitting multiple sclerosis
- Substances:Ocrelizumab
Countries:Italy
Italy- Participants:18–64 years
- Substances:Ocrelizumab
Not yet recruiting
Dementia Alzheimer's type
Not yet recruitingRegistered drug
Study on BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia
Registered drug
- Disease:Dementia Alzheimer's type
- Substances:Florbetaben (18F)Flutemetamol (18F)+1
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Florbetaben (18F)
Not recruiting
Dementia Alzheimer's type
Not recruitingInvestigationalNo placebo
A Study to Test the Long-term Safety and Benefits of GSK4527226 in Patients with Early Alzheimer's Disease
InvestigationalNo placebo
- Disease:Dementia Alzheimer's type
- Substances:Gsk4527226
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Gsk4527226
Not recruiting
Multiple sclerosis
Not recruitingInvestigational
Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis
Investigational
- Disease:Multiple sclerosis
- Substances:Frexalimab
Countries:Italy
Italy- Participants:18–64 years
- Substances:Frexalimab
Not recruiting
Study on the Effectiveness and Safety of DFL24412 and Ketoprofen Lysine in Patients with Chronic Low Back Pain
Not recruitingRegistered drugNo placebo
Study on the Effectiveness and Safety of DFL24412 and Ketoprofen Lysine in Patients with Chronic Low Back Pain
Registered drugNo placebo
- Substances:GabapentinKetoprofen Lysine+1
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Gabapentin